Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening Epstein-Barr virus (EBV)-driven B-cell malignancy occurring in 1 to 3% of renal transplant patients. Recently, EBV DNA quantification has become a useful tool for identifying patients at risk of developing PTLD. However, studies on EBV load differ in design, methodology and type of patients.

Malignancy was transferred inadvertently to two patients, each of whom received a renal transplant from a cadaver donor who was found at necropsy to have a small, clinically silent carcinoma of lung. Both recipients died with metastatic bronchial carcinoma of the same histological type as the donor's tumour. The literature on transplanted malignancy is reviewed.

conclusions by controlling the modifiable risk factors and modality of treatment in our study, physicians can reach more effective treatment. results at the end of the study, long-term graft failure was seen in 27 (10.2%) cases. one-year and 2-year graft survival after diagnosis of cancer were 93.6% and 91.7%, respectively. the univariate analysis showed that the incidence of chronic graft loss...

Immunosuppressive treatment increases the risk of infection and malignancy in organ transplant recipients. We report on a 42-year-old male renal transplant recipient who lost his first graft after reduction of immunosuppressive treatment due to Kaposi sarcoma and who successfully underwent a second renal transplant 10 years later. The patient's current treatment consists of low-dose prednisone,...

Post-transplant malignancy is a major cause of late mortality for liver transplant recipients (LTRs). This nationwide population-based cohort study investigated the cancer type, incidence, and risk factors associated with post-transplant malignancies in 2938 Taiwanese LTRs who underwent transplantation between 1998 and 2012. Data from the National Health Insurance Research Database were extract...

The goals of post-transplant management are to manage and treat postoperative complications, and develop a balanced long-term immunotherapy regimen that minimizes infection and side effects but controls rejection. While modern immunosuppressant regimes have reduced rates of graft loss due to rejection, they impart major risks for infection, growth failure, metabolic complications, and malignanc...

introduction: the long-term use of immunosuppressive agents for prevention of allograft rejection increases the risk of malignancy approximately 100 times as high as that in the general population and kaposi’s sarcoma (ks) is a relatively common malignancy after kidney transplantation. the aim of present study was to investigate the frequency of ks in patients with kidney transplantation in 20 ...

zygomycosis is a fulminant infection which usually afflicts patients who are immunocompromised by diabetes mellitus, malignancy or immunosuppressive therapy.l this disease is a rare but highly invasive fungal infection which occurs in organ transplant recipients. 2 mucormycosis confined to the gastrointestinal tract is an uncommon form of the disease. accounting for only seven percent of all mu...

Of 364 patients with lymphoid malignancy who underwent high-dose therapy with autologous bone marrow transplantation (ABMT) or peripheral stem cell transplantation (PSCT), 169 patients have had progressive disease after the procedure. The median survival from the time of relapse for patients with Hodgkin's disease (HD) who progressed after the transplant was 10.5 months. This compares with a me...